cubist pharmaceuticals

Cubist Pharmaceuticals' (NASDAQ: CBST) 2011 sales revenue guidance was 3-6% higher than Jefferies' estimate. “Better-than-expected Cubicin sales guidance is positive (vs. our conservative assumptions),” Jefferies writes. “Focus is on Cubicin patent litigation resolution (trial date 4/25/11). We...

Cubist Pharmaceuticals (NASDAQ: CBST) reported flat sales in 3Q, and Oppenheimer has adjusted estimates in response to lower operating expenses. In a research report, Oppenheimer writes "On 10/14, CBST reported 3Q10 EPS of $0.53 vs. our estimate of $0.47 and consensus of $0.41. Although Cubicin...

Jefferies & Co. published a research report on Cubist Pharmaceuticals (NASDAQ: CBST) in anticipation of the company's 3Q results. In the report, Jefferies writes "We're positive on CBST given (1) Cubicin sales growth prospects (12% CAGR for '09-'14); (2) likely positive outcome from Cubicin...